Biogen Inc (BIIB) : Js Capital Management scooped up 22,500 additional shares in Biogen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 34,500 shares of Biogen Inc which is valued at $10,830,930.Biogen Inc makes up approximately 6.15% of Js Capital Management’s portfolio.
Other Hedge Funds, Including , Northcoast Asset Management reduced its stake in BIIB by selling 16,912 shares or 10.93% in the most recent quarter. The Hedge Fund company now holds 137,775 shares of BIIB which is valued at $43,253,084. Biogen Inc makes up approx 3.52% of Northcoast Asset Management’s portfolio.Ithaka Group boosted its stake in BIIB in the latest quarter, The investment management firm added 30 additional shares and now holds a total of 25,046 shares of Biogen Inc which is valued at $7,862,941. Biogen Inc makes up approx 1.05% of Ithaka Group’s portfolio.Segall Bryant Hamill reduced its stake in BIIB by selling 213 shares or 0.95% in the most recent quarter. The Hedge Fund company now holds 22,108 shares of BIIB which is valued at $6,940,586. Biogen Inc makes up approx 0.18% of Segall Bryant Hamill’s portfolio. Frontier Wealth Management sold out all of its stake in BIIB during the most recent quarter. The investment firm sold 982 shares of BIIB which is valued $308,289.Mariner Investment Group reduced its stake in BIIB by selling 11,000 shares or 58.88% in the most recent quarter. The Hedge Fund company now holds 7,682 shares of BIIB which is valued at $2,468,534. Biogen Inc makes up approx 0.80% of Mariner Investment Group’s portfolio.
Biogen Inc opened for trading at $307.96 and hit $309.25 on the upside on Thursday, eventually ending the session at $306.03, with a gain of 0.13% or 0.4 points. The heightened volatility saw the trading volume jump to 10,68,034 shares. Company has a market cap of $67,058 M.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Downgraded by Jefferies to ” Hold” on Sep 6, 2016. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.